168 related articles for article (PubMed ID: 14568919)
1. Virus evasion of MHC class I molecule presentation.
Petersen JL; Morris CR; Solheim JC
J Immunol; 2003 Nov; 171(9):4473-8. PubMed ID: 14568919
[No Abstract] [Full Text] [Related]
2. Molecular mechanisms of viral immune evasion proteins to inhibit MHC class I antigen processing and presentation.
Zhou F
Int Rev Immunol; 2009; 28(5):376-93. PubMed ID: 19811316
[TBL] [Abstract][Full Text] [Related]
3. MHC class I antigen presentation: learning from viral evasion strategies.
Hansen TH; Bouvier M
Nat Rev Immunol; 2009 Jul; 9(7):503-13. PubMed ID: 19498380
[TBL] [Abstract][Full Text] [Related]
4. [Viral strategies of interference with MHC functions].
Ishido S; Goto E; Sato Y; Hotta H
Tanpakushitsu Kakusan Koso; 2002 Dec; 47(16 Suppl):2145-51. PubMed ID: 12518428
[No Abstract] [Full Text] [Related]
5. Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells.
Hengel H; Esslinger C; Pool J; Goulmy E; Koszinowski UH
J Gen Virol; 1995 Dec; 76 ( Pt 12)():2987-97. PubMed ID: 8847504
[TBL] [Abstract][Full Text] [Related]
6. Modulation of host immune responses by clinically relevant human DNA and RNA viruses.
Brander C; Walker BD
Curr Opin Microbiol; 2000 Aug; 3(4):379-86. PubMed ID: 10972498
[TBL] [Abstract][Full Text] [Related]
7. From Recoding to Peptides for MHC Class I Immune Display: Enriching Viral Expression, Virus Vulnerability and Virus Evasion.
Atkins JF; O'Connor KM; Bhatt PR; Loughran G
Viruses; 2021 Jun; 13(7):. PubMed ID: 34199077
[TBL] [Abstract][Full Text] [Related]
8. Transport and expression of class I MHC glycoproteins in an antigen-processing mutant cell line.
Click EM; Anderson KS; Androlewicz MJ; Wei ML; Cresswell P
Cold Spring Harb Symp Quant Biol; 1992; 57():571-7. PubMed ID: 1339695
[No Abstract] [Full Text] [Related]
9. Polymorphism at position nine of the MHC class I heavy chain affects the stability of association with beta 2-microglobulin and presentation of a viral peptide.
Ribaudo RK; Margulies DH
J Immunol; 1995 Oct; 155(7):3481-93. PubMed ID: 7561043
[TBL] [Abstract][Full Text] [Related]
10. A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation.
Reusch U; Muranyi W; Lucin P; Burgert HG; Hengel H; Koszinowski UH
EMBO J; 1999 Feb; 18(4):1081-91. PubMed ID: 10022849
[TBL] [Abstract][Full Text] [Related]
11. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
Roemer MG; Advani RH; Redd RA; Pinkus GS; Natkunam Y; Ligon AH; Connelly CF; Pak CJ; Carey CD; Daadi SE; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Shipp MA; Rodig SJ
Cancer Immunol Res; 2016 Nov; 4(11):910-916. PubMed ID: 27737878
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of class I assembly with beta 2 microglobulin and loading with peptide.
Hansen TH; Lee DR
Adv Immunol; 1997; 64():105-37. PubMed ID: 9100981
[No Abstract] [Full Text] [Related]
13. Human cytomegalovirus protein pp71 disrupts major histocompatibility complex class I cell surface expression.
Trgovcich J; Cebulla C; Zimmerman P; Sedmak DD
J Virol; 2006 Jan; 80(2):951-63. PubMed ID: 16378997
[TBL] [Abstract][Full Text] [Related]
14. A complex between the MHC class I homologue encoded by human cytomegalovirus and beta 2 microglobulin.
Browne H; Smith G; Beck S; Minson T
Nature; 1990 Oct; 347(6295):770-2. PubMed ID: 2172831
[TBL] [Abstract][Full Text] [Related]
15. Viral immune evasion molecules attack the ER peptide-loading complex and exploit ER-associated degradation pathways.
Lybarger L; Wang X; Harris M; Hansen TH
Curr Opin Immunol; 2005 Feb; 17(1):71-8. PubMed ID: 15653314
[TBL] [Abstract][Full Text] [Related]
16. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens.
Ackerman AL; Kyritsis C; Tampé R; Cresswell P
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12889-94. PubMed ID: 14561893
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of MHC class I-restricted antigen processing and cross-presentation.
Cresswell P; Ackerman AL; Giodini A; Peaper DR; Wearsch PA
Immunol Rev; 2005 Oct; 207():145-57. PubMed ID: 16181333
[TBL] [Abstract][Full Text] [Related]
18. Viral interference with MHC class I antigen presentation pathway: the battle continues.
Ambagala AP; Solheim JC; Srikumaran S
Vet Immunol Immunopathol; 2005 Aug; 107(1-2):1-15. PubMed ID: 15978672
[TBL] [Abstract][Full Text] [Related]
19. Processing of exogenous hepatitis B surface antigen particles for Ld-restricted epitope presentation depends on exogenous beta2-microglobulin.
Schirmbeck R; Thoma S; Reimann J
Eur J Immunol; 1997 Dec; 27(12):3471-84. PubMed ID: 9464837
[TBL] [Abstract][Full Text] [Related]
20. Reversal of fortune for nascent proteins.
Bonifacino JS
Nature; 1996 Dec; 384(6608):405-6. PubMed ID: 8945460
[No Abstract] [Full Text] [Related]
[Next] [New Search]
